117 - 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN¿S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION Geert D¿Haens; Remo Panaccione; Julián Panés; Tadakazu Hisamatsu; Peter Bossuyt; Silvio Danese; Ezequiel Neimark; Alexandra Song; Xiaomei Liao; Kori Wallace; Javier Zambrano; W Rachel Duan; Kristina Kligys; Marla Dubinsky;

111 - EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U- EXCEL STUDY Edward V. Loftus; Jean-Frederic Colombel; Ana Paula Lacerda; Laurent Peyrin-Biroulet; Geert D¿Haens; Remo Panaccione; Walter Reinisch; Edouard Louis; Minhu Chen; Hiroshi Nakase; Susan Greenbloom; George DuVall; Yuri Sánchez González; Mohamed-Eslam F. Mohamed; Susan Rhee; Tian Feng; Elena Dubcenco; Julián Panés;

114 - EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U- ENDURE MAINTENANCE STUDY Julián Panés; Edward V. Loftus; Ana Lacerda; Laurent Peyrin- Biroulet; Geert D¿Haens; Remo Panaccione; Walter Reinisch; Edouard Louis; Minhu Chen; Hiroshi Nakase; Jakob Begun; Brigid S. Boland; Jianzhong Liu; Elena Dubcenco; Mohamed-Eslam F. Mohamed; Tian Feng; Jean-Frederic Colombel;